钠-葡萄糖协同转运蛋白2抑制剂改善脂肪营养不良并发症：一例报告 - Suppr

Suppr

超能文献

Sodium-Glucose Cotransporter 2 Inhibitor Improves Complications of Lipodystrophy: A Case Report.

作者信息

Kawana Yohei, Imai Junta, Sawada Shojiro, Yamada Tetsuya, Katagiri Hideki

机构信息

From Tohoku University Hospital, Sendai, Japan.

出版信息

Ann Intern Med. 2017 Mar 21;166(6):450-451. doi: 10.7326/L16-0372.

DOI:10.7326/L16-0372

PMID:28320010

Abstract

摘要

相似文献

Sodium-Glucose Cotransporter 2 Inhibitor Improves Complications of Lipodystrophy: A Case Report.钠-葡萄糖协同转运蛋白2抑制剂改善脂肪营养不良并发症：一例报告

Ann Intern Med. 2017 Mar 21;166(6):450-451. doi: 10.7326/L16-0372.

Long-term efficacy of the sodium-glucose cotransporter 2 inhibitor, ipragliflozin, in a case of type A insulin resistance syndrome.钠-葡萄糖共转运蛋白 2 抑制剂伊格列净治疗 A 型胰岛素抵抗综合征 1 例的长期疗效。

J Diabetes Investig. 2020 Sep;11(5):1363-1365. doi: 10.1111/jdi.13241. Epub 2020 Mar 20.

Effect of canagliflozin, a sodium-glucose cotransporter 2 inhibitor, on measurement of serum 1,5-anhydroglucitol.钠-葡萄糖协同转运蛋白2抑制剂卡格列净对血清1,5-脱水葡萄糖醇测定的影响。

J Diabetes. 2014 Jul;6(4):378-80. doi: 10.1111/1753-0407.12116. Epub 2014 Feb 25.

Ameliorated pancreatic β cell dysfunction in type 2 diabetic patients treated with a sodium-glucose cotransporter 2 inhibitor ipragliflozin.用钠-葡萄糖协同转运蛋白2抑制剂依帕列净治疗的2型糖尿病患者胰腺β细胞功能障碍得到改善。

Endocr J. 2015;62(1):77-86. doi: 10.1507/endocrj.EJ14-0335. Epub 2014 Oct 17.

[Therapy resistant diabetes mellitus and lipodystrophy: leptin therapy leads to improvement].[治疗抵抗性糖尿病和脂肪营养不良：瘦素治疗可带来改善]

Ned Tijdschr Geneeskd. 2013;157(4):A5482.

Clinical Effects of Sodium-Glucose Transporter Type 2 Inhibitors in Patients With Partial Lipodystrophy.2型钠-葡萄糖协同转运蛋白抑制剂对部分性脂肪营养不良患者的临床疗效

Endocr Pract. 2022 Jun;28(6):610-614. doi: 10.1016/j.eprac.2022.03.006. Epub 2022 Mar 14.

Case Report: Metreleptin and SGLT2 Inhibitor Combination Therapy Is Effective for Acquired Incomplete Lipodystrophy.病例报告：米雷替肽与 SGLT2 抑制剂联合治疗对获得性不完全性脂肪营养不良有效。

Front Endocrinol (Lausanne). 2021 May 31;12:690996. doi: 10.3389/fendo.2021.690996. eCollection 2021.

Renal threshold for glucose reabsorption predicts diabetes improvement by sodium-glucose cotransporter 2 inhibitor therapy.葡萄糖重吸收的肾阈值可预测钠-葡萄糖协同转运蛋白2抑制剂治疗对糖尿病的改善情况。

J Diabetes Investig. 2016 Sep;7(5):751-4. doi: 10.1111/jdi.12473. Epub 2016 Feb 16.

A Lower Baseline Urinary Glucose Excretion Predicts a Better Response to the Sodium Glucose Cotransporter 2 Inhibitor.较低的基础尿糖排泄预示着对钠-葡萄糖共转运蛋白 2 抑制剂有更好的反应。

Diabetes Metab J. 2019 Dec;43(6):898-905. doi: 10.4093/dmj.2018.0257. Epub 2019 Jun 14.

Ipragliflozin , a sodium-glucose cotransporter 2 inhibitor, in the treatment of type 2 diabetes.依帕列净，一种钠-葡萄糖协同转运蛋白2抑制剂，用于治疗2型糖尿病。

Expert Opin Drug Metab Toxicol. 2015 Apr;11(4):613-23. doi: 10.1517/17425255.2015.1009893. Epub 2015 Feb 2.

引用本文的文献

Diagnosis and Management of Genetic Lipodystrophy Syndromes and its Implications for Atherosclerosis.遗传性脂肪营养不良综合征的诊断与管理及其对动脉粥样硬化的影响

Curr Atheroscler Rep. 2025 May 13;27(1):55. doi: 10.1007/s11883-025-01301-2.

A multicenter, open-label, single-arm trial of the long-term safety of empagliflozin treatment for refractory diabetes mellitus with insulin resistance (EMPIRE-02).一项评估恩格列净治疗伴胰岛素抵抗的难治性糖尿病长期安全性的多中心、开放标签、单臂临床试验（EMPIRE-02）。

J Diabetes Investig. 2024 Sep;15(9):1211-1219. doi: 10.1111/jdi.14226. Epub 2024 May 4.

Diabetes mellitus with severe insulin resistance in a young male patient with a heterozygous pathogenic frameshift variant.一名年轻男性患者患有杂合致病性移码变异，伴有严重胰岛素抵抗的糖尿病。

Clin Pediatr Endocrinol. 2024;33(2):87-93. doi: 10.1297/cpe.2023-0081. Epub 2024 Feb 23.

A Multicenter, Open-Label, Single-Arm Trial of the Efficacy and Safety of Empagliflozin Treatment for Refractory Diabetes Mellitus with Insulin Resistance (EMPIRE-01).恩格列净治疗伴有胰岛素抵抗的难治性糖尿病的疗效和安全性多中心、开放标签、单臂试验（EMPIRE-01）

Diabetes Ther. 2024 Feb;15(2):533-545. doi: 10.1007/s13300-023-01526-x. Epub 2024 Jan 13.

Genotype-stratified treatment for monogenic insulin resistance: a systematic review.单基因胰岛素抵抗的基因型分层治疗：一项系统评价

Commun Med (Lond). 2023 Oct 5;3(1):134. doi: 10.1038/s43856-023-00368-9.

Systematic review of genotype-stratified treatment for monogenic insulin resistance.单基因胰岛素抵抗的基因型分层治疗的系统评价

medRxiv. 2023 Apr 21:2023.04.17.23288671. doi: 10.1101/2023.04.17.23288671.

Treatment Options for Lipodystrophy in Children.儿童脂肪营养不良的治疗选择。

Front Endocrinol (Lausanne). 2022 May 4;13:879979. doi: 10.3389/fendo.2022.879979. eCollection 2022.

Clinical Effects of Sodium-Glucose Transporter Type 2 Inhibitors in Patients With Partial Lipodystrophy.2型钠-葡萄糖协同转运蛋白抑制剂对部分性脂肪营养不良患者的临床疗效

Endocr Pract. 2022 Jun;28(6):610-614. doi: 10.1016/j.eprac.2022.03.006. Epub 2022 Mar 14.

Front Endocrinol (Lausanne). 2021 May 31;12:690996. doi: 10.3389/fendo.2021.690996. eCollection 2021.

Coexistence of ovarian serous papillary cystadenofibroma and type A insulin resistance syndrome in a 14-year-old girl: A case report.一名14岁女孩卵巢浆液性乳头状囊腺纤维瘤与A型胰岛素抵抗综合征并存：病例报告

World J Clin Cases. 2020 Aug 6;8(15):3334-3340. doi: 10.12998/wjcc.v8.i15.3334.

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验